医学
结直肠癌
内科学
肿瘤科
阶段(地层学)
随机对照试验
回顾性队列研究
总体生存率
队列
倾向得分匹配
腺癌
癌症
临床试验
结肠腺癌
队列研究
病历
癌症登记处
外科
大肠腺癌
多中心试验
仿真
多元分析
存活率
作者
K Chen,Donghao Xu,Z G Zhang,F Y Liang,G D He,Jianmin Xu,Q Y Feng
出处
期刊:JCO oncology practice
[Lippincott Williams & Wilkins]
日期:2026-05-04
卷期号:: OP2501296-OP2501296
被引量:1
摘要
PURPOSE Renin-angiotensin system inhibitors (RASIs) have been reported to exert anticancer effects. However, there is still a lack of persuasive evidence for their role in improving postoperative long-term oncologic outcomes of colorectal cancer. This retrospective cohort study emulated a hypothetical randomized controlled trial to evaluate the efficacy of RASIs in improving postoperative long-term oncologic outcomes of patients with stage II/III colon cancer and hypertension. METHODS Patients were consecutively enrolled from multicenter databases, which contained data from medical centers in Shanghai, China. Eligible criteria were adults with radical resected stage II or III colon adenocarcinoma and hypertension. Eligible patients were classified into the RASI group or the no-RASI group, and propensity score was matched at a 1:1 ratio. The primary outcome was the 3-year disease-free survival (DFS) rate. RESULTS From 2,640 eligible patients, 2,292 were included in the primary analysis after matching: 1,146 in the RASI group and 1,146 in the no-RASI group. The median follow-up time was 46.3 months. The RASI group had a higher 3-year DFS rate (83.4% v 78.3%; P = .001; hazard ratio [HR], 0.736 [95% CI, 0.617 to 0.878]). The RASI group also had a lower 3-year distant metastasis rate (15.6% v 20.5%; P < .001; HR, 0.717 [95% CI, 0.596 to 0.863]) and a higher 3-year overall survival rate (92.4% v 89.6%; P = .001; HR, 0.682 [95% CI, 0.539 to 0.864]). CONCLUSION RASIs may improve the postoperative long-term oncologic outcomes for patients with stage II/III colon cancer and hypertension.
科研通智能强力驱动
Strongly Powered by AbleSci AI